| Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination (NCT05422508) | Green Cross Corporation | 2022-07-05 |
| Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (NCT05158777) | Shanghai Institute Of Biological Products | 2022-02-13 |
| An Immunity Persistence Study of Live Attenuated Varicella Vaccine (NCT05095701) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2021-12-18 |
| Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (NCT05015686) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2021-09-30 |
| A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine (NCT05526820) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2021-04-08 |
| Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) (NCT03843632) | Merck Sharp & Dohme LLC | 2019-03-01 |
| An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization (NCT05150392) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2018-07-11 |
| Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) (NCT03239873) | Merck Sharp & Dohme LLC | 2017-10-17 |
| Pediatric and Ambulatory Research in Infectious Diseases (NCT04471493) | Association Clinique Thérapeutique Infantile du val de Marne | 2017-06-26 |
| Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine (NCT03330171) | University of Witwatersrand, South Africa | 2017-04-10 |
| A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines (NCT02981836) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2016-08-01 |
| Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age (NCT03114943) | SK Bioscience Co., Ltd. | 2016-07-14 |
| The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age (NCT03114982) | SK Chemicals Co., Ltd. | 2016-05-01 |
| Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine. (NCT02692066) | University of Colorado, Denver | 2016-04-01 |
| A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children (NCT02965404) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2016-04-01 |
| Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (NCT01991899) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2015-02-01 |
| A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062) (NCT01626794) | Merck Sharp & Dohme LLC | 2014-07-01 |
| Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine (NCT02173899) | Changchun Keygen Biological Products Co., Ltd. | 2014-06-01 |
| A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine (NCT03555071) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2014-04-07 |
| Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) (NCT02062502) | Merck Sharp & Dohme LLC | 2014-03-07 |
| Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (NCT01738841) | GlaxoSmithKline | 2013-08-01 |
| The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination (NCT01866566) | Beijing Center for Disease Control and Prevention | 2013-06-01 |
| The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination (NCT01830283) | Beijing Center for Disease Control and Prevention | 2013-04-01 |
| Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine (NCT02146469) | Shanghai Municipal Center for Disease Control and Prevention | 2012-12-01 |
| Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) (NCT01536405) | Merck Sharp & Dohme LLC | 2012-06-05 |
| Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (NCT01506193) | GlaxoSmithKline | 2012-02-06 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV (NCT01190228) | Sanofi Pasteur, a Sanofi Company | 2010-08-25 |
| Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM (NCT00969436) | GlaxoSmithKline | 2009-11-09 |
| Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds (NCT00892775) | GlaxoSmithKline | 2009-06-03 |
| Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery (NCT00926419) | University of Sao Paulo General Hospital | 2009-06-01 |
| Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) (NCT00822237) | Merck Sharp & Dohme LLC | 2009-01-01 |
| Safety of a Second Dose of Biken's Varicella Vaccine (NCT00830648) | Sanofi Pasteur, a Sanofi Company | 2009-01-01 |
| A Study of ProQuad™ in Healthy Children in Korea (V221-023) (NCT00839917) | Merck Sharp & Dohme LLC | 2008-02-01 |
| Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) (NCT00566527) | Merck Sharp & Dohme LLC | 2007-11-29 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age (NCT00578175) | GlaxoSmithKline | 2007-11-20 |
| Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox) (NCT01390857) | GlaxoSmithKline | 2007-11-01 |
| Study of Two Formulations of GSK Biologicals' Varicella Vaccine (NCT00568334) | GlaxoSmithKline | 2007-11-01 |
| Safety Study of ProQuad® rHA in Infants (V221-037) (NCT00560755) | Merck Sharp & Dohme LLC | 2007-10-24 |
| Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients (NCT00715234) | University of Colorado, Denver | 2007-10-01 |
| Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients (NCT00492739) | University Hospital, Geneva | 2007-06-01 |
| Re-examination Study For Varivax (V210-059 AM2) (NCT01062061) | Merck Sharp & Dohme LLC | 2007-06-01 |
| Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers (NCT00483574) | Sanofi Pasteur, a Sanofi Company | 2007-05-01 |
| Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (NCT00432042) | Merck Sharp & Dohme LLC | 2007-01-12 |
| Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers (NCT00422292) | Sanofi Pasteur, a Sanofi Company | 2006-12-01 |
| ProQuad® Intramuscular vs Subcutaneous (NCT00402831) | Merck Sharp & Dohme LLC | 2006-10-06 |
| A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers (NCT00384397) | Sanofi Pasteur, a Sanofi Company | 2006-09-01 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ (NCT00352898) | GlaxoSmithKline | 2006-04-01 |
| Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes (NCT00351923) | GlaxoSmithKline | 2006-03-01 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ (NCT00353288) | GlaxoSmithKline | 2006-03-01 |
| V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) (NCT00109343) | Merck Sharp & Dohme LLC | 2006-03-01 |
| Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection (NCT00338442) | Cangene Corporation | 2006-02-01 |
| Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (NCT00127010) | GlaxoSmithKline | 2005-11-01 |
| Immune Responses to Two Dose Varivax +/- MMR-II (NCT00258726) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox (NCT00226499) | GlaxoSmithKline | 2005-09-01 |
| Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) (NCT00496327) | Merck Sharp & Dohme LLC | 2005-06-22 |
| Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients (NCT00127608) | GlaxoSmithKline | 2005-06-07 |
| Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (NCT00126997) | GlaxoSmithKline | 2005-05-01 |
| Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (NCT00127023) | GlaxoSmithKline | 2005-05-01 |
| Evaluation Of Valaciclovir In Patients With Chickenpox (NCT00169416) | GlaxoSmithKline | 2005-03-01 |
| Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) (NCT00432523) | Merck Sharp & Dohme LLC | 2005-01-20 |
| Safety Study of a Refrigerator-stable Formulation of VARIVAX® (NCT00432731) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine (NCT00406211) | GlaxoSmithKline | 2004-07-01 |
| Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines (NCT00138255) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-06-01 |
| Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). (NCT00792623) | GlaxoSmithKline | 2003-09-08 |
| Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) (NCT00092430) | Merck Sharp & Dohme LLC | 2002-09-26 |
| Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) (NCT00092404) | Merck Sharp & Dohme LLC | 2001-12-01 |
| A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) (NCT00985166) | Merck Sharp & Dohme LLC | 2000-08-01 |
| Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines (NCT00984295) | Merck Sharp & Dohme LLC | 2000-06-01 |
| Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) (NCT00985153) | Merck Sharp & Dohme LLC | 2000-03-01 |
| ProQuad Dose Selection Study (V221-011)(COMPLETED) (NCT00986232) | Merck Sharp & Dohme LLC | 1999-04-01 |
| A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) (NCT00092391) | Merck Sharp & Dohme LLC | 1999-02-01 |
| ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) (NCT00975507) | Merck Sharp & Dohme LLC | 1998-03-01 |
| A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED) (NCT01077804) | Merck Sharp & Dohme LLC | 1995-06-01 |
| Tai Chi Chih and Varicella Zoster Immunity (NCT00029484) | National Center for Complementary and Integrative Health (NCCIH) | |